Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Operations (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Cash from Operations data on record, last reported at 5347000.0 in Q2 2025.

  • For Q2 2025, Cash from Operations fell 38.65% year-over-year to 5347000.0; the TTM value through May 2025 reached 206000.0, down 180.16%, while the annual FY2025 figure was 206000.0, 180.16% down from the prior year.
  • Cash from Operations reached 5347000.0 in Q2 2025 per LFCR's latest filing, up from 1200000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 8716000.0 in Q2 2024 and bottomed at 16435000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 2354277.78, with a median of 1635000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: crashed 656.49% in 2023, then skyrocketed 485.32% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 5685000.0 in 2021, then soared by 58.61% to 2353000.0 in 2022, then soared by 154.74% to 1288000.0 in 2023, then crashed by 576.71% to 6140000.0 in 2024, then surged by 187.08% to 5347000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 5347000.0 in Q2 2025, 1200000.0 in Q1 2025, and 6140000.0 in Q4 2024.